MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

115.43 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
News headline image
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility ↗
Via The Motley Fool
Topics Artificial Intelligence Government
News headline image
Unpacking the Latest Options Trading Trends in Merck & Co ↗
 
Via Benzinga
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Via The Motley Fool
Topics Stocks
News headline image
Price Over Earnings Overview: Merck & Co ↗
 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in Merck & Co ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Merck & Co? ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals ↗
MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors. 
Via Chartmill
News headline image
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials ↗
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported. 
Via Benzinga
News headline image
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish ↗
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide. 
Via Stocktwits
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Top S&P500 movers in Monday's pre-market session ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
From Merck & Co., Inc.
Via Business Wire
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Each of the index's highest-yielding names has its own unique story right now. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
1 Value Stock to Target This Week and 2 to Question
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover ↗
The deal is being discussed ahead of key data from MoonLake in patients with a skin disease. 
Via Investor's Business Daily
News headline image
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report ↗
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff. 
Via Benzinga
Topics Intellectual Property
News headline image
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers ↗
Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile. 
Via Benzinga
News headline image
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure ↗
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
News headline image
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’ ↗
The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated. 
Via Stocktwits
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story